628 related articles for article (PubMed ID: 26589398)
1. Novel therapeutic targets in advanced urothelial carcinoma.
Rouanne M; Loriot Y; Lebret T; Soria JC
Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
4. Update of systemic immunotherapy for advanced urothelial carcinoma.
Gartrell BA; He T; Sharma J; Sonpavde G
Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
[TBL] [Abstract][Full Text] [Related]
5. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
6. The landscape of immunotherapy in metastatic urothelial carcinoma.
Teo MY; Iyer G
Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
8. [Update 2016 - Immunotherapy for urothelial carcinoma].
Retz M; Gschwend JE; Schmid SC
Urologe A; 2016 Feb; 55(2):246-52. PubMed ID: 26767648
[TBL] [Abstract][Full Text] [Related]
9. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Ikeda S; Hansel DE; Kurzrock R
Cancer Treat Rev; 2015 Sep; 41(8):699-706. PubMed ID: 26138514
[TBL] [Abstract][Full Text] [Related]
10. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
Teo MY; Rosenberg JE
Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
[TBL] [Abstract][Full Text] [Related]
11. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
Schmid SC; Koll FJ; Beckert F; Seitz AK
Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
13. Prime time for immunotherapy in advanced urothelial cancer.
Jiang DM; Sridhar SS
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():24-32. PubMed ID: 30489031
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
15. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
Giridhar KV; Kohli M
Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
[TBL] [Abstract][Full Text] [Related]
16. [Molecular subtype classification of urothelial bladder cancer and its clinical relevance].
Szarvas T; Oláh C; Riesz P; Géczi L; Nyirády P
Orv Hetil; 2019 Oct; 160(42):1647-1654. PubMed ID: 31608691
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in advanced bladder cancer: what have we learned?
Jordan EJ; Iyer G
Urol Clin North Am; 2015 May; 42(2):253-62, ix. PubMed ID: 25882566
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in treatment of advanced urothelial carcinoma.
Kim JJ
Curr Urol Rep; 2012 Apr; 13(2):147-52. PubMed ID: 22367511
[TBL] [Abstract][Full Text] [Related]
19. Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.
Liu MA; Li JW; Runcie K
Curr Oncol Rep; 2024 May; 26(5):496-503. PubMed ID: 38602581
[TBL] [Abstract][Full Text] [Related]
20. Individualized management of advanced bladder cancer: Where do we stand?
Burgess EF
Urol Oncol; 2015 Apr; 33(4):187-95. PubMed ID: 24332641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]